Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Ibrutinib in CLL at Risk of Progression
NCT02912754Phase 2Unknown
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Mar 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Maximum Tolerated Dose at 2 years. Status: unknown.
02
Drugs
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02912754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912754.